Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Allergan plc (NYSE:AGN)

Tuesday’s trading has closed, but AGN is being traded in the after-hours session. After-Hours quote »
Delayed Data
As of 4:01pm ET
 +6.04 / +2.27%
Today’s Change
Today|||52-Week Range
Health Technology
Pharmaceuticals: Generic

Company Description

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. The firm offers products under the following brands: BOTOX, Juvederm, Linzess, Namenda, Restasis, Latisse, Teflaro, Lo Loestrin Fe, Bystolic, DORYX, Saphris, Fetzima, Namenda XR, Namzaric, Viberzi, Viibryd, Alphagan, LUMIGAN, ESTRACE Cream, Rapaflo, Asacol, DELZICOL, Zenpep, Avycaz, and Dalvance. Its brand portfolio delivers treatments that address unmet medical needs in therapeutic categories such as dermatology and aesthetics; central nervous system; eye care; women health and urology; gastroenterology and cystic fibrosis; and cardiovascular and infectious disease. The company was founded on October 1, 2012 and is headquartered in Dublin, Ireland.

Contact Information

Allergan Plc
Clonshaugh Business & Tech. Park
Dublin Dublin D17 E400
Investor Relations:
(862) 261-7152



Other institutional49.98%
Mutual fund holders43.62%
Individual stakeholders0.10%

Top Executives

Brenton L. SaundersPresident, Chief Executive Officer & Director
Robert A. StewartPresident-Generic & Global Operations, EVP
Maria Teresa HiladoChief Financial Officer & Executive Vice President
Jonathon KellermanGlobal Chief Compliance Officer & Executive VP
Karen L. LingChief Human Resources Officer & Executive VP